Skip to main content

Advertisement

SpringerLink
Log in

Orthopedic Uses of Teriparatide

  • Published:
Current Osteoporosis Reports Aims and scope Submit manuscript

Abstract

Teriparatide is a drug currently approved for treating patients with osteoporosis who are at high risk for future fracture. In the treatment of osteoporosis, teriparatide works as an anabolic agent stimulating bone formation throughout the skeleton by principally enhancing osteoblast-derived bone formation relative to osteoclast-derived bone resorption. The net effect is increased bone mass. For patients with a fracture, a similar process of increased bone formation is required transiently at the fracture site for repair. Teriparatide has been investigated in animal models and in patients as a potential agent to enhance fracture repair. In addition, evidence that teriparatide enhances chondrogenesis has generated interest in using the agent for articular cartilage repair. Research is currently underway to understand the effects teriparatide may have on mesenchymal stem cells, and on other effects that have been reported anecdotally in patients using the drug for osteoporosis care, including the healing of fracture nonunions and a decreased incidence of back pain. We review the current animal and human reports available on the uses of teriparatide in musculoskeletal diseases beyond osteoporosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: •• Of major importance

  1. Burge RT, Dawson-Hughes B, Solomon D, et al.: Incidence and economic burden of osteoporotic fractures in the United States, 2005–2025. J Bone Min Res 2007, 22:465–475.

    Article  Google Scholar 

  2. Kent GN, Loveridge N, Reeve J, et al.: Pharmacokinetics of synthetic human parathyroid hormone 1-34 in man measured by cytochemical bioassay and radioimmunoassay. Clin Sci (Lond) 1985, 68:171–177.

    CAS  Google Scholar 

  3. Hock JM, Gera I: Effects of continuous and intermittent administration and inhibition of resorption on the anabolic response of bone to parathyroid hormone. J Bone Miner Res 1992, 7:65–72.

    Article  CAS  PubMed  Google Scholar 

  4. Dempster DW, Cosman F, Kurland ES, et al.: Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res 2001, 16:1846–1853.

    Article  CAS  PubMed  Google Scholar 

  5. Barnes GL, Kostenuik PJ, Gerstenfeld LC, Einhorn TA: Growth factor regulation of fracture repair. J Bone Miner Res 1999, 14:1805–1815.

    Article  CAS  PubMed  Google Scholar 

  6. Simmons DJ: Fracture healing perspectives. Clin Orthop Relat Res 1985, 200:100–113.

    PubMed  Google Scholar 

  7. Kronenberg HM, Chung U: The parathyroid hormone-related protein and Indian hedgehog feedback loop in the growth plate. Novartis Found Symp 2001, 232:144–152.

    Article  CAS  PubMed  Google Scholar 

  8. Andreassen TT, Ejersted C, Oxlund H: Intermittent parathyroid hormone (1-34) treatment increases callus formation and mechanical strength of healing rat fractures. J Bone Miner Res 1999, 14:960–968.

    Article  CAS  PubMed  Google Scholar 

  9. Andreassen TT, Willick GE, Morley P, Whitfield JF: Treatment with parathyroid hormone hPTH(1-34), hPTH (1-31), and monocyclic hPTH(1-31) enhances fracture strength and callus amount after withdrawal fracture strength and callus mechanical quality continue to increase. Calcif Tissue Int 2004, 74:351–356.

    Article  CAS  PubMed  Google Scholar 

  10. Alkhiary YM, Gerstenfeld LC, Krall E, et al.: Enhancement of experimental fracture-healing by systemic administration of recombinant human parathyroid hormone (PTH 1-34). J Bone Joint Surg Am 2005, 87:731–741.

    Article  PubMed  Google Scholar 

  11. Manabe T, Mori S, Mashiba T, et al.: Human parathyroid hormone (1-34) accelerates natural fracture healing process in the femoral osteotomy model of cynomolgus monkeys. Bone 2007, 40:1475–1482.

    Article  CAS  PubMed  Google Scholar 

  12. Friedl G, Turner RT, Evans GL, Dobnig H: Intermittent parathyroid hormone (PTH) treatment and age-dependent effects on rat cancellous bone and mineral metabolism. J Orthop Res 2007, 25:1454–1464.

    Article  CAS  PubMed  Google Scholar 

  13. Rickard DJ, Wang FL, Rodriques-Rojas AM, et al.: Intermittent treatment with parathyroid hormone (PTH) as well as a non-peptide small molecule agonist of the PTH1 receptor inhibits adipocyte differentiation in human bone marrow stromal cells. Bone 2006, 39:1361–1372.

    Article  CAS  PubMed  Google Scholar 

  14. Nakazawa T, Makajima A, Shiomi K, et al.: Effects of low-dose, intermittent treatment with recombinant human parathyroid hormone (1-34) on chondrogenesis in a model of experimental fracture healing. Bone 2005, 37:711–719.

    Article  CAS  PubMed  Google Scholar 

  15. Kakar S, Einhorn TA, Vora S, et al.: Enhanced chondrogenesis and Wnt signaling in PTH-treated fractures. J Bone Miner Res 2007, 22:1903–1912.

    Article  CAS  PubMed  Google Scholar 

  16. O’Loughlin PF, Cunningham ME, Bukata SV, et al.: Parathyroid hormone (1-34) augments spinal fusion, fusion mass volume, and fusion mass quality in a rabbit spinal fusion model. Spine 2009, 34:121–130.

    Article  PubMed  Google Scholar 

  17. •• Aspenberg P, Genant HK, Johansson T, et al.: Teriparatide for acceleration of fracture repair in humans: a prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures. J Bone Miner Res 2009 Jul 13 [Epub ahead of print]. This is the first placebo-controlled, double-blinded, randomized clinical trial investigating the use of teriparatide in humans to accelerate fracture healing. Although this study missed its primary end point with a dose greater than that which is used for osteoporosis, the trend for the dose currently used for osteoporosis suggests an effect. It is a fundamental study that all subsequent trials investigating biologic adjuvants for fracture healing will need to use as a comparator.

  18. Resmini G, Iolascon G: 79-year-old post-menopausal woman with humerus fracture during teriparatide treatment. Aging Clin Exp Res 2007, 19(4 Suppl):30–31.

    PubMed  Google Scholar 

  19. Bukata SV, Kaback L, Reynolds D, et al.: 1-34 PTH at physiologic doses in humans shows promise as a helpful adjuvant in difficult to heal fractures: an observational cohort of 145 patients. Presented at the 55th Annual Meeting of the Orthopaedic Research Society. Las Vegas, NV; February 25, 2009.

  20. Peichl P, Krankenhaus Wien-Waehring E, Holzer G: Parathyroid hormone 1-84 accelerates fracture healing in pubic bones of elderly osteoporotic women. J Bone Miner Res 24(Suppl 1). Available at http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=9d4e83f0-6302-4327-8a9d-758dc56cc703. Accessed January 2010.

  21. Desai A, Alavi A, Dalinka M, et al.: Role of bone scintigraphy in the evaluation and treatment on nonunited fractures: concise communication. J Nucl Med 1980, 21:931–934.

    CAS  PubMed  Google Scholar 

  22. •• Chang JK, Chang LH, Hung SH, et al.: Parathyroid hormone 1-34 inhibits terminal differentiation of human articular chondrocytes and osteoarthritis progression in rats. Arthritis Rheum 2009, 60:3049–3060. This is the first animal study published looking at the potential role that teriparatide may play in treating early arthritis.

  23. Sampson E, Ho CH, Awad H, et al.: Intermittent PTH(1-34) and PTHrP enhance hyaline cartilage regeneration in a rabbit full-thickness defect model. J Bone Miner Res 24(Suppl 1). Available at http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=71a2723d-3c7d-41b4-aea0-bc1b5abfc65d. Accessed January 2010.

  24. Sampson E, O’Brien T, Awad H, et al.: PTH(1-34) protects against articular cartilage degeneration following meniscal/ligamentous injury in a mouse model of osteoarthritis. J Bone Miner Res 24(Suppl 1). Available at http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=b4d2b7bb-8741-485f-8792-853794628e8a. Accessed January 2010.

  25. Nevitt MC, Chen P, Dore RK, et al.: Reduced risk of back pain following teriparatide treatment: a meta-analysis. Osteoporos Int 2006, 17:273–280.

    Article  PubMed  Google Scholar 

Download references

Disclosure

Dr. Susan Bukata is on the speakers’ bureau and has done consulting for Eli Lilly; she has also done consulting for Amgen. Dr. J. Edward Puzas has done consulting for Eli Lilly and Novartis.

Author information

Authors and Affiliations

  1. School of Medicine and Dentistry, University of Rochester, 601 Elmwood Avenue, Box 665, Rochester, NY, 14642, USA

    Susan V. Bukata & J. Edward Puzas

Authors
  1. Susan V. Bukata
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Edward Puzas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Susan V. Bukata.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bukata, S.V., Puzas, J.E. Orthopedic Uses of Teriparatide. Curr Osteoporos Rep 8, 28–33 (2010). https://doi.org/10.1007/s11914-010-0006-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11914-010-0006-3

Keywords

Search

Navigation